Penka, M <br/><br/>
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine].  [electronic resource] 

 -  Vnitrni lekarstvi   
 - 775-82 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0042-773X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Fibrinolytic Agents--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Myeloproliferative Disorders--blood<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Count<br/>Quinazolines--adverse effects<br/>Risk Assessment<br/>Thrombocythemia, Essential--blood<br/>Thrombocytopenia--complications<br/>Thrombosis--etiology